Related Experiment Video
Updated: Oct 14, 2025

Receptor Autoradiography Protocol for the Localized Visualization of Angiotensin II Receptors
Published on: June 7, 2016
Angiotensin II Type 1 Receptor Tachyphylaxis Is Defined by Agonist Residence Time
Diego A Duarte1, Lucas T Parreiras-E-Silva1, Eduardo B Oliveira1
1Department of Biochemistry and Immunology, Ribeirao Preto Medical School, University of São Paulo, Ribeirão Preto, Brazil (D.A.D., L.T.P.-e.-S., E.B.O., C.M.C.-N.).
Abstract:
Several GPCRs (G-protein-coupled receptors) have been reported to exhibit tachyphylaxis, which is an acute loss of functional receptor response after repeated stimuli with an agonist. GPCRs are important clinical targets for a wide range of disorders. Therefore, elucidation of the ligand features that contribute to receptor tachyphylaxis and signaling events underlying this phenomenon is important for drug discovery and development. In this study, we examined the role of ligand-binding kinetics in the tachyphylaxis of AT1R (angiotensin II type 1 receptor) using bioluminescence resonance energy transfer assays to monitor signaling events under both kinetic and equilibrium conditions. We investigated AT1R signal transduction and translocation promoted by the endogenous tachyphylactic agonist Ang II (angiotensin II) and its analogs, described previously for inducing reduced receptor tachyphylaxis. Estimation of binding kinetic parameters of the ligands revealed that the residence time of Ang II was higher than that of the analogs, resulting in more sustained Gq protein activation and recruitment of β-arrestin than that promoted by the analogs. Furthermore, we observed that Ang II led to more sustained internalization of the receptor, thereby retarding its recycling to the plasma membrane and preventing further receptor responses. These results show that the apparent lack of tachyphylaxis in the studied analogs resulted from their short residence time at the AT1R. In addition, our data highlight the relevance of complete characterization of novel GPCR drug candidates, taking into account their receptor binding kinetics as well.
Insights
Ligand residence time at G-protein-coupled receptors (GPCRs) influences tachyphylaxis. Short residence times, like those of angiotensin II analogs, prevent sustained signaling and receptor desensitization.
Area of Science:
- Pharmacology
- Molecular Biology
- Biochemistry
Background:
- G-protein-coupled receptors (GPCRs) are crucial drug targets, but tachyphylaxis limits their therapeutic potential.
- Understanding ligand features causing GPCR tachyphylaxis is vital for drug discovery.
- Angiotensin II type 1 receptor (AT1R) is a key target in cardiovascular diseases.
Purpose of the Study:
- To investigate the role of ligand-binding kinetics in AT1R tachyphylaxis.
- To compare signaling events induced by angiotensin II (Ang II) and its analogs.
- To elucidate how ligand residence time affects receptor desensitization.
Main Methods:
- Bioluminescence resonance energy transfer (BRET) assays were used to monitor AT1R signaling.
- Ligand-binding kinetic parameters were estimated for Ang II and its analogs.
- Receptor translocation, Gq protein activation, and beta-arrestin recruitment were analyzed.
Main Results:
- Ang II exhibited a longer residence time at AT1R compared to its analogs.
- Sustained Gq protein activation and beta-arrestin recruitment were observed with Ang II.
- Ang II promoted prolonged receptor internalization, hindering recycling and subsequent responses.
Conclusions:
- The lack of tachyphylaxis with Ang II analogs is attributed to their short residence time at AT1R.
- Ligand residence time is a critical determinant of GPCR tachyphylaxis.
- Comprehensive characterization of GPCR drug candidates, including binding kinetics, is essential for development.
More Related Videos
09:51Live Cell Imaging and 3D Analysis of Angiotensin Receptor Type 1a Trafficking in Transfected Human Embryonic Kidney Cells Using Confocal Microscopy
Published on: March 27, 2017
08:35Improved Renal Denervation Mitigated Hypertension Induced by Angiotensin II Infusion
Published on: May 26, 2022
Related Concept Videos
Antihypertensive Drugs: Angiotensin II Receptor Blockers
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
Desensitization and Tachyphylaxis
Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors
Antihypertensive Drugs: Direct Renin Inhibitors
Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...